Array Celebrates BEACON Of Hope For Anti-BRAF/MEK/EGFR Triplet In Colorectal Cancer

New data on Array BioPharma's encorafenib and binimetinib together with cetuximab add hopes for its future in colorectal cancer. Recent strong data in melanoma for the BRAF/MEK combo are expected to be followed by its first US approval in the coming days.

a beautiful beacon appears on a foggy day
Beacon of hope for Array in CRC

Overall survival data from Array BioPharma Inc.'s Phase III BEACON CRC safety lead-in trial of its BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and Eli Lilly & Co./Merck KGaA's anti-EGFR antibody Erbitux (cetuximab) suggest the triplet combination could prove valuable as a treatment for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Array reported at the European Society of Medical Oncology's gastrointestinal cancer conference (ESMO-GI) in Barcelona June 23 that the combo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?